NCT02257138View on ClinicalTrials.gov

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 12, 2015

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Blasts More Than 20 Percent of Bone Marrow Nucleated CellsBlasts More Than 20 Percent of Peripheral Blood White CellsMyelodysplastic/Myeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Decitabine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Ruxolitinib Phosphate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02257138 - Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter